Compare QH & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | XCUR |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 9.2M |
| IPO Year | 2019 | 2017 |
| Metric | QH | XCUR |
|---|---|---|
| Price | $3.35 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.3K | ★ 15.3K |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.94 |
| 52 Week High | $12.81 | $9.48 |
| Indicator | QH | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 43.50 |
| Support Level | $3.00 | $1.05 |
| Resistance Level | $4.07 | $1.48 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 30.57 | 50.70 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.